Neurocrine Biosciences Inc. (NBIX)

84.18
NASDAQ : Health Technology
Prev Close 86.97
Day Low/High 83.00 / 88.34
52 Wk Low/High 68.22 / 126.98
Avg Volume 832.60K
Exchange NASDAQ
Shares Outstanding 90.68M
Market Cap 7.89B
EPS -1.60
P/E Ratio 790.64
Div & Yield N.A. (N.A)

Latest News

Neurocrine Biosciences Reports Third Quarter 2018 Financial Results

Neurocrine Biosciences Reports Third Quarter 2018 Financial Results

INGREZZA® (valbenazine) Third Quarter Net Product Sales of $111.3 Million with Approximately 19,400 TRx

Neurocrine Biosciences To Present New Data Analyses On The Long-Term Effects Of INGREZZA® (valbenazine) In Tardive Dyskinesia Patients With Mood Disorders At The 2018 Annual Psych Congress

Neurocrine Biosciences To Present New Data Analyses On The Long-Term Effects Of INGREZZA® (valbenazine) In Tardive Dyskinesia Patients With Mood Disorders At The 2018 Annual Psych Congress

New Data Also Examine the Impact of Uncontrollable Movements as Reported by Patients, Caregivers and Healthcare Providers from RE-KINECT, the Largest Real-World Screening Study of Patients with Possible Tardive Dyskinesia

Neurocrine Biosciences Announces Conference Call And Webcast Of Third Quarter 2018 Financial Results

Neurocrine Biosciences Announces Conference Call And Webcast Of Third Quarter 2018 Financial Results

Conference Call and Webcast Scheduled for Monday, November 5

Neurocrine Biosciences And Jnana Therapeutics Enter Strategic Collaboration To Discover Novel Medicines To Treat Central Nervous System Disorders

Neurocrine Biosciences And Jnana Therapeutics Enter Strategic Collaboration To Discover Novel Medicines To Treat Central Nervous System Disorders

Partnership Leverages Neurocrine's Expertise in Neuroscience and Jnana's Proprietary Drug Discovery Platform Targeting the Solute Carrier Family of Transporters

Neurocrine Biosciences To Present New Long-Term Data Analyses On INGREZZA® (valbenazine) At The 2018 International Congress Of Parkinson's Disease And Movement Disorders

Neurocrine Biosciences To Present New Long-Term Data Analyses On INGREZZA® (valbenazine) At The 2018 International Congress Of Parkinson's Disease And Movement Disorders

New Long-Term Data from Phase III KINECT 4 Study Highlights Efficacy of INGREZZA Across Body Regions in Patients with Tardive Dyskinesia

Neurocrine Biosciences To Present At The Morgan Stanley 16th Annual Global Healthcare Conference

Neurocrine Biosciences To Present At The Morgan Stanley 16th Annual Global Healthcare Conference

Live Audio Webcast will be on September 12, 2018

AbbVie Announces Positive Topline Results From Phase 3 Extension Study Evaluating Investigational Elagolix In Women With Uterine Fibroids

AbbVie Announces Positive Topline Results From Phase 3 Extension Study Evaluating Investigational Elagolix In Women With Uterine Fibroids

- Study results (ELARIS UF-EXTEND) showed elagolix, in combination with add-back therapy, reduced heavy menstrual bleeding for up to 12 months

Neurocrine Biosciences To Present Data On INGREZZA® (valbenazine) And Opicapone At The 2018 World Congress On Parkinson's Disease And Related Disorders

Neurocrine Biosciences To Present Data On INGREZZA® (valbenazine) And Opicapone At The 2018 World Congress On Parkinson's Disease And Related Disorders

New Long-Term Analyses Highlight Patient-Reported Outcomes and Patient Satisfaction with INGREZZA for the Treatment of Tardive Dyskinesia

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AJRD, BXP, CARB, CDR, DOC, FTAI, GHDX, GOV, HOME, IKNX, LOCO, NBIX, NYLD.A, RFP, UEIC Downgrades: APU, HY, MFNC, SGMS, TFX Initiations: EEX, SSTI Read on to get TheStreet Quant Ratings' detailed report:

Neurocrine Biosciences Reports Second Quarter 2018 Financial Results

Neurocrine Biosciences Reports Second Quarter 2018 Financial Results

INGREZZA® (valbenazine) Second Quarter Net Product Sales of $96.9 Million with Approximately 16,700 TRx

3 'Strong Buy' Healthcare Stocks Poised to Surge

3 'Strong Buy' Healthcare Stocks Poised to Surge

Here are the top healthcare bets ticking all the boxes for analysts.

AbbVie Receives U.S. FDA Approval Of ORILISSA™ (elagolix) For The Management Of Moderate To Severe Pain Associated With Endometriosis

AbbVie Receives U.S. FDA Approval Of ORILISSA™ (elagolix) For The Management Of Moderate To Severe Pain Associated With Endometriosis

- ORILISSA™ (elagolix) is the first FDA-approved oral treatment for the management of moderate to severe pain associated with endometriosis in over a decade

Neurocrine Biosciences Announces Conference Call And Webcast Of Second Quarter 2018 Financial Results

Neurocrine Biosciences Announces Conference Call And Webcast Of Second Quarter 2018 Financial Results

Conference Call and Webcast Scheduled for Tuesday, July 31

5 Stocks That Are Screaming Buys Right Now

5 Stocks That Are Screaming Buys Right Now

Stay active and selective: These are the five best stocks to invest in right now

Spring Cleaning: Let's Tidy Up Some Trades

Spring Cleaning: Let's Tidy Up Some Trades

Not every trade can be a winner, so let's lighten the load here.

A Bullish Play on Neurocrine Biosciences

A Bullish Play on Neurocrine Biosciences

Analysts weren't shy to defend the company after Tuesday's earnings.

Tuesday Investor Blog: Is the Bull Market in Stocks Being Ripped to Shreds?

Tuesday Investor Blog: Is the Bull Market in Stocks Being Ripped to Shreds?

Bring your A-game in these markets or go home. Just keeping it real. Here is what you need to know on Tuesday.

15 Biotech Firms That Have Strong Potential to Be Acquired: Jefferies

15 Biotech Firms That Have Strong Potential to Be Acquired: Jefferies

'Balance sheets are flush with cash and there is a need to grow for large health care companies,' Jefferies analysts wrote.

Watch These Biotechs and the FDA Calendar

Watch These Biotechs and the FDA Calendar

Here are a few key events I will be watching closely for in the months ahead on stocks I think are buys at current levels.

3 Key Biotech Catalysts on the FDA Calendar

3 Key Biotech Catalysts on the FDA Calendar

A roundup of biotech names with actions pending at the FDA in coming weeks.

Who Benefits From Tax Reform?

Who Benefits From Tax Reform?

Technology and biotech companies seem to be among the big winners.

Neurocrine Biosciences Soars on Third-Quarter Results -- Biotech Movers

Neurocrine Biosciences Soars on Third-Quarter Results -- Biotech Movers

The San Diego firm said net product sales of Ingrezza, a treatment for tardive dyskinesia, were $45.8 million during the quarter. The FDA approved Ingrezza in April.

10 Sectors That Will Profit Big-Time From Oil's Crash

10 Sectors That Will Profit Big-Time From Oil's Crash

Oil prices are tumbling down. Bad news for companies and petro states, but great news at the pump and for these ten industries...

Short Interest In Neurocrine Biosciences Increases 16%

The most recent short interest data has been released for the 06/15/2017 settlement date, which shows a 1,118,638 share increase in total short interest for Neurocrine Biosciences, Inc. , to 8,122,994, an increase of 15.97% since 05/31/2017.

Biotech Movers: Inovio, Neurocrine, Alnylam

Biotech Movers: Inovio, Neurocrine, Alnylam

Inovio Pharmaceuticals, Neurocrine Biosciences and Alnylam Pharmaceuticals were among the biotech movers in premarket trading on Wednesday.

Week in Review: Wall Street Sees Red as Geopolitical Issues Dominate, Earnings Begin

Week in Review: Wall Street Sees Red as Geopolitical Issues Dominate, Earnings Begin

Geopolitical concerns dominated market moves as banks kicked off earnings season.

U.S. Markets Close Lower as Wall Street Frets Over Global Turmoil

U.S. Markets Close Lower as Wall Street Frets Over Global Turmoil

Stocks closed lower Wednesday as markets continue to grapple with geopolitical uncertainty.

Wall Street Closes Lower Amid Continued Global Worries

Wall Street Closes Lower Amid Continued Global Worries

Stocks closed lower Wednesday as markets continue to grapple with geopolitical uncertainty.

TheStreet Quant Rating: C (Hold)